Literature DB >> 10910012

Problems with currently available antidepressants.

J F Gumnick1, C B Nemeroff.   

Abstract

Although options for pharmacologic treatment for depression have grown seemingly exponentially over the past several decades, the current armamentarium of antidepressants continues to have limitations of both efficacy and tolerability. The problems include an unacceptable lack of efficacy, delayed onset of therapeutic effects, an inability to predict responses to one or another agent, drug-drug interactions, and difficulty with tolerability during both acute and chronic treatment. This article reviews the problems that persist in the use of currently available antidepressant medications and presents a list of attributes that would be characteristic of the ideal antidepressant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910012

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  A novel prodrug strategy to improve the oral absorption of O-desmethylvenlafaxine.

Authors:  Mingyuan Liu; Yantong Sun; Sen Zhao; Youxin Li; Riyang Piao; Yan Yang; Jingkai Gu
Journal:  Exp Ther Med       Date:  2016-06-14       Impact factor: 2.447

3.  Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines.

Authors:  Jose A Morón; Alicia Brockington; Roy A Wise; Beatriz A Rocha; Bruce T Hope
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

4.  Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

Authors:  Horrick Sharma; Soumava Santra; Joy Debnath; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2013-11-19       Impact factor: 3.641

5.  Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects.

Authors:  Stephan Chalon; Alvaro Pereira; Eric Lainey; François Vandenhende; John G Watkin; Luc Staner; Luc-André Granier
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

6.  LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.

Authors:  Zheng Zhou; Juan Zhen; Nathan K Karpowich; Regina M Goetz; Christopher J Law; Maarten E A Reith; Da-Neng Wang
Journal:  Science       Date:  2007-08-09       Impact factor: 47.728

Review 7.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 8.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

9.  Multi-Watt Near-Infrared Phototherapy for the Treatment of Comorbid Depression: An Open-Label Single-Arm Study.

Authors:  Theodore A Henderson; Larry D Morries
Journal:  Front Psychiatry       Date:  2017-09-29       Impact factor: 4.157

10.  Potassium 2-(1-hydroxypentyl)-benzoate improves depressive-like behaviors in rat model.

Authors:  Hao Ma; Weiping Wang; Shaofeng Xu; Ling Wang; Xiaoliang Wang
Journal:  Acta Pharm Sin B       Date:  2018-08-20       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.